Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Jul 24, 2026, 2:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Abdominal Malignancy Clear all
Withdrawn Not applicable Interventional Accepts healthy volunteers

Paracervical Vasopressin Injection Compared With Intramyometrial Vasopressin in Abdominal Myomectomy

NCT02377492
View directory record Official record
Conditions
Myoma
Interventions
Vasopressins
Drug
Lead sponsor
University Hospitals Cleveland Medical Center
Other
Eligibility
18 Years to 60 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2015
U.S. locations
2
States / cities
Beachwood, Ohio • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated May 11, 2022 · Synced Jul 24, 2026, 2:05 AM EDT
Completed Early Phase 1 Interventional

Digital Meditation for Postoperative Pain Control After Abdominal Surgery for Cancer

NCT05346692
View directory record Official record
Conditions
Hematopoietic and Lymphoid System Neoplasm, Malignant Solid Neoplasm
Interventions
Survey Administration, Interview, Text Message-Based Navigation Intervention
Other
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
73 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jan 13, 2025 · Synced Jul 24, 2026, 2:05 AM EDT
Completed Phase 1 Interventional

Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis

NCT03508570
View directory record Official record
Conditions
Malignant Peritoneal Neoplasm, Malignant Retroperitoneal Neoplasm, Metastatic Cervical Carcinoma, Metastatic Endometrial Carcinoma, Metastatic Fallopian Tube Carcinoma, Metastatic Malignant Female Reproductive System Neoplasm, Metastatic Ovarian Carcinoma, Metastatic Primary Peritoneal Carcinoma, Peritoneal Carcinomatosis, Platinum-Refractory Fallopian Tube Carcinoma, Platinum-Refractory Malignant Female Reproductive System Neoplasm, Platinum-Refractory Ovarian Carcinoma, Platinum-Refractory Primary Peritoneal Carcinoma, Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Malignant Female Reproductive System Neoplasm, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Cervical Carcinoma, Recurrent Endometrial Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Malignant Female Reproductive System Neoplasm, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IV Primary Peritoneal Cancer AJCC v8, Stage IVA Fallopian Tube Cancer AJCC v8, Stage IVA Ovarian Cancer AJCC v8, Stage IVA Primary Peritoneal Cancer AJCC v8, Stage IVB Cervical Cancer AJCC v8, Stage IVB Fallopian Tube Cancer AJCC v8, Stage IVB Ovarian Cancer AJCC v8, Stage IVB Primary Peritoneal Cancer AJCC v8, Stage IVB Uterine Corpus Cancer AJCC v8
Interventions
Ipilimumab, Laboratory Biomarker Analysis, Nivolumab, Pharmacokinetic Study
Biological · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 21, 2025 · Synced Jul 24, 2026, 2:05 AM EDT
Completed Phase 3 Interventional Results available

An Ovarian, Primary Peritoneal or Fallopian Tube Cancer Study for Patients That Have Not Received Prior Chemotherapy

NCT00191646
View directory record Official record
Conditions
Genital Neoplasms, Female, Fallopian Tube Neoplasms, Ovarian Neoplasms, Pelvic Neoplasms, Peritoneal Neoplasms
Interventions
Gemcitabine, Paclitaxel, Carboplatin
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older · Female only
Enrollment
919 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2009
U.S. locations
54
States / cities
Phoenix, Arizona • Little Rock, Arkansas • Los Gatos, California + 51 more
Source: ClinicalTrials.gov public record
Updated Mar 3, 2011 · Synced Jul 24, 2026, 2:05 AM EDT
Completed Phase 2 Interventional

Pegylated Interferon Alfa-2a Salvage Therapy in High Risk Polycythemia Vera (PV) or Essential Thrombocythemia (ET)

NCT01259817
View directory record Official record
Conditions
High Risk Polycythemia Vera, High Risk Essential Thrombocythemia
Interventions
PEGASYS, Aspirin
Drug
Lead sponsor
Ronald Hoffman
Other
Eligibility
18 Years and older
Enrollment
135 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
16
States / cities
Scottsdale, Arizona • Palo Alto, California • Washington D.C., District of Columbia + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Jul 24, 2026, 2:05 AM EDT
Active, not recruiting Phase 3 Interventional

Relacorilant in Combination With Nab-Paclitaxel in Advanced, Platinum-Resistant, High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian-Tube Cancer

NCT05257408
View directory record Official record
Conditions
Ovarian Neoplasm, Fallopian Tube Neoplasms, Peritoneal Neoplasms
Interventions
Nab-paclitaxel 80 mg/m^2, Relacorilant 150 mg once daily (QD), Nab-paclitaxel 100 mg/m^2
Drug
Lead sponsor
Corcept Therapeutics
Industry
Eligibility
18 Years and older · Female only
Enrollment
381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2026
U.S. locations
44
States / cities
Phoenix, Arizona • Tucson, Arizona • Irvine, California + 35 more
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Jul 24, 2026, 2:05 AM EDT
Active, not recruiting No phase listed Observational

Evaluation of Atherosclerotic Plaques in Abdominal CT Studies

NCT04652973
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Not listed
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
30 Years to 90 Years
Enrollment
118 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2030
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2025 · Synced Jul 24, 2026, 2:05 AM EDT
Completed No phase listed Observational

HIPEC For Peritoneal Surface Malignancies Including Carcinomatosis or Sarcomatosis - Data Registry

NCT02082886
View directory record Official record
Conditions
Peritoneal Neoplasms, Neoplasm Metastasis, Adenocarcinoma, Sarcoma
Interventions
Not listed
Lead sponsor
Edward-Elmhurst Health System
Other
Eligibility
Not listed
Enrollment
193 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
2
States / cities
Elmhurst, Illinois • Naperville, Illinois
Source: ClinicalTrials.gov public record
Updated Jan 28, 2020 · Synced Jul 24, 2026, 2:05 AM EDT
Recruiting Phase 2 Interventional

Heated Versus Aerosol-based Laparoscopic Chemotherapy for Cancer That Has Spread to the Peritoneum (Abdominal Lining)

NCT07282834
View directory record Official record
Conditions
Peritoneal (Metastatic) Cancer, Peritoneal Carcinomatosis, Abdominal Cancer, Abdominal Cancer Patients
Interventions
Heated intra-peritoneal chemotherapy, Aerosolized intra-peritoneal chemotherapy
Procedure
Lead sponsor
Patrick Wagner, MD, FACS
Other
Eligibility
18 Years to 80 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2040
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 26, 2026 · Synced Jul 24, 2026, 2:05 AM EDT
Not listed Phase 3 Interventional Accepts healthy volunteers

A Comparison of Exparel to Bupivacaine in TAP Block for Abdominal Gynecologic Surgery

NCT03304444
View directory record Official record
Conditions
Gynecologic Cancer, Post Operative Pain
Interventions
Bupivacaine, liposomal bupivacaine
Drug
Lead sponsor
Abington Memorial Hospital
Other
Eligibility
18 Years to 99 Years · Female only
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Abington, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Oct 8, 2017 · Synced Jul 24, 2026, 2:05 AM EDT
Terminated Phase 2 Interventional

Malignant Mixed Mesodermal Tumor (MMMT) - Early Stage With Postoperative XRT/Chemotherapy

NCT00505492
View directory record Official record
Conditions
Uterine Neoplasms
Interventions
Carboplatin, Cisplatin, Paclitaxel
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
Female only
Enrollment
4 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
2
States / cities
Houston, Texas • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Sep 14, 2011 · Synced Jul 24, 2026, 2:05 AM EDT
Recruiting No phase listed Observational Accepts healthy volunteers

Integrated Cancer Repository for Cancer Research

NCT02012699
View directory record Official record
Conditions
Pancreatic Cancer, Thyroid Cancer, Lung Cancer, Esophageal Cancer, Thymus Cancer, Colon Cancer, Rectal Cancer, Gastrointestinal Stromal Tumors, Anal Cancer, Bile Duct Cancer, Duodenal Cancer, Gallbladder Cancer, Gastric Cancer, Liver Cancer, Small Intestine Cancer, Peritoneal Surface Malignancies, Familial Adenomatous Polyposis, Lynch Syndrome, Bladder Cancer, Kidney Cancer, Penile Cancer, Prostate Cancer, Testicular Cancer, Ureter Cancer, Urethral Cancer, Hypopharyngeal Cancer, Laryngeal Cancer, Lip Cancer, Oral Cavity Cancer, Nasopharyngeal Cancer, Oropharyngeal Cancer, Paranasal Sinus Cancer, Nasal Cavity Cancer, Salivary Gland Cancer, Skin Cancer, Central Nervous System Tumor, Central Nervous System Cancer, Mesothelioma, Breast Cancer, Leukemia, Melanoma, Sarcoma, Unknown Primary Tumor, Multiple Myeloma, Ovarian Cancer, Endometrial Cancer, Vaginal Cancer, Neuroendocrine Tumors, Plasma Cell Dyscrasia, Healthy Control
Interventions
Not listed
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years to 110 Years
Enrollment
999,999 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2099
U.S. locations
42
States / cities
Greenwood Village, Colorado • Manchester, Connecticut • Daytona Beach, Florida + 34 more
Source: ClinicalTrials.gov public record
Updated Jun 28, 2026 · Synced Jul 24, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Thalidomide in Treating Patients Who Have Undergone Surgery and Chemotherapy for Cancer That Has Spread Throughout the Abdomen Due to Colorectal Cancer or Appendix Cancer

NCT00310076
View directory record Official record
Conditions
Carcinoma of the Appendix, Colorectal Cancer
Interventions
thalidomide, surgery
Drug · Procedure
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 120 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2012
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 22, 2018 · Synced Jul 24, 2026, 2:05 AM EDT
Recruiting Phase 1 Interventional

Intraperitoneal Paclitaxel With NALIRIFOX for Pancreatic Ductal Adenocarcinoma With Peritoneal Carcinomatosis

NCT07030283
View directory record Official record
Conditions
Pancreatic Ductal Adenocarcinoma (PDAC)
Interventions
Paclitaxel, NALIRIFOX
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2030
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 1, 2026 · Synced Jul 24, 2026, 2:05 AM EDT
Not listed No phase listed Observational

Desmoid Tumor and Pregnancy: Effect of Pregnancy on Disease Control and Effect of Diagnosis on Pregnancy History.

NCT05284305
View directory record Official record
Conditions
Desmoid, Desmoid; Abdominal, Pregnancy Loss, Pregnancy Complications
Interventions
Pregnancy
Other
Lead sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Other
Eligibility
18 Years and older · Female only
Enrollment
400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2023
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 26, 2023 · Synced Jul 24, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Clinical Trial of Docetaxel in Combination With Gemcitabine in Platinum-Resistant Ovarian Cancer and Primary Peritoneal Carcinoma

NCT00183794
View directory record Official record
Conditions
Ovarian Carcinoma, Peritoneal Neoplasms
Interventions
Docetaxel and Gemcitabine
Drug
Lead sponsor
University of Southern California
Other
Eligibility
18 Years and older · Female only
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 21, 2014 · Synced Jul 24, 2026, 2:05 AM EDT
Completed Phase 1 Interventional

A Phase 1 Study of CC-486 as a Single Agent and in Combination With Carboplatin or ABI-007 in Subjects With Relapsed or Refractory Solid Tumors

NCT01478685
View directory record Official record
Conditions
Urinary Bladder Neoplasms, Carcinoma, Transitional Cell, Ovarian Neoplasms, Fallopian Tube Neoplasms, Peritoneal Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Pancreatic Ductal, Tumor Virus Infections
Interventions
CC-486, Carboplatin, ABI-007
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older
Enrollment
169 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
7
States / cities
Scottsdale, Arizona • San Francisco, California • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 11, 2019 · Synced Jul 24, 2026, 2:05 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Adipose Tissue and Polycystic Ovary Syndrome (PCOS)(EIFFEL)

NCT01745471
View directory record Official record
Conditions
Polycystic Ovary Syndrome, Metabolic Diseases, Overweight
Interventions
Not listed
Lead sponsor
AdventHealth Translational Research Institute
Other
Eligibility
20 Years to 40 Years · Female only
Enrollment
36 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2025
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Aug 2, 2025 · Synced Jul 24, 2026, 2:05 AM EDT
Completed Phase 1 Interventional

Interleukin-12 in Treating Patients With Refractory Advanced-Stage Ovarian Cancer or Abdominal Cancer

NCT00003439
View directory record Official record
Conditions
Cancer
Interventions
recombinant interleukin-12
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 1998
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 6, 2013 · Synced Jul 24, 2026, 2:05 AM EDT
Completed Phase 3 Interventional Results available

A Study Comparing the Combination of Trabectedin (YONDELIS) and DOXIL/CAELYX With DOXIL/CAELYX for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

NCT01846611
View directory record Official record
Conditions
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
Interventions
Trabectedin, DOXIL, Dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
75
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 72 more
Source: ClinicalTrials.gov public record
Updated Mar 31, 2019 · Synced Jul 24, 2026, 2:05 AM EDT
Terminated Phase 1 Interventional

ABI-007 With Carboplatin as First-Line Therapy in Patients With Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Carcinoma

NCT00407407
View directory record Official record
Conditions
Fallopian Tube Neoplasms, Peritoneal Neoplasms, Ovarian Neoplasms
Interventions
ABI-007, Carboplatin
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years and older · Female only
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Oct 17, 2019 · Synced Jul 24, 2026, 2:05 AM EDT
Completed Phase 2 Interventional Results available

Surgery and Heated Chemotherapy for Adrenocortical Carcinoma

NCT01833832
View directory record Official record
Conditions
Adrenocortical Carcinoma, Peritoneal Carcinomatosis
Interventions
Cisplatin, Cytoreductive surgery, sodium thiosulfate
Drug · Procedure
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years to 99 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jul 29, 2019 · Synced Jul 24, 2026, 2:05 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Olvi-Vec Oncolytic Immunotherapy in Patients With Recurrent or Refractory Ovarian Cancer

NCT02759588
View directory record Official record
Conditions
Ovarian Cancer, Peritoneal Carcinomatosis, Fallopian Tube Cancer
Interventions
Olvi-Vec, Platinum-doublet with or without bevacizumab
Biological · Drug
Lead sponsor
Genelux Corporation
Industry
Eligibility
21 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2022
U.S. locations
2
States / cities
Newport Beach, California • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Jun 11, 2026 · Synced Jul 24, 2026, 2:05 AM EDT
Completed Phase 1 Interventional

Combination Chemotherapy Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer

NCT00005840
View directory record Official record
Conditions
Endometrial Clear Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Stage III Uterine Corpus Cancer, Stage IV Uterine Corpus Cancer
Interventions
Paclitaxel, Cisplatin, Radiation Therapy
Drug · Radiation
Lead sponsor
Gynecologic Oncology Group
Network
Eligibility
18 Years and older · Female only
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2000
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Dec 30, 2014 · Synced Jul 24, 2026, 2:05 AM EDT